Amneal Pharmaceuticals
Open
$16.34
Prev. Close
$16.33
High
$16.34
Low
$16.19
Market Snapshot
$5.1B
41.7
-0.38
$2.79B
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,500 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Amneal Pharmaceuticals is experiencing significant investor interest, evidenced by a 17.8% stock increase this week, reflecting strong performance in the pharmaceutical industry.
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. The company is headquartered in Bridgewater, New Jersey and currently employs 8,500 full-time employees. The company went IPO on 2009-11-18. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Recently from Cashu
Amneal Pharmaceuticals Acquires Kashiv BioSciences to Strengthen Biosimilars Portfolio and Growth Prospects
Amneal Pharmaceuticals makes strategic moves to strengthen its position in the biosimilars market, unveiling its acquisition of Kashiv BioSciences. This pivotal acquisition will incorporate over 20 bi…
Amneal Pharmaceuticals to Announce Q4 2024 Financial Results on February 28, 2025
Amneal Pharmaceuticals Prepares for Upcoming Financial Results Announcement Amneal Pharmaceuticals, Inc., a global biopharmaceutical company headquartered in Bridgewater, NJ, is set to release its fou…
Amneal Pharmaceuticals Prepares for Major Investor Conferences in December 2024 and January 2025
Amneal Pharmaceuticals Gears Up for Key Investor Conferences Amneal Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is set to showcase its leadership at two major upcoming in…
Amneal Pharmaceuticals Prepares for Investor Conferences to Highlight Expansion and Growth Strategy
Amneal Pharmaceuticals Prepares for Key Investor Conferences Amid Expansion Efforts Amneal Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry based in Bridgewater, NJ, is gearing…